Targeted Oncology
Latest Publications

TOTAL DOCUMENTS

852

(FIVE YEARS 162)

H-INDEX

(FIVE YEARS 5)

Published By Springer-Verlag

1776-260x, 1776-2596

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Targeted Oncology ◽

10.1007/s11523-021-00865-8 ◽

2022 ◽

Author(s):

Monia Sisi ◽

Michele Fusaroli ◽

Andrea De Giglio ◽

Francesco Facchinetti ◽

Andrea Ardizzoni ◽

...

Keyword(s):

Adverse Reactions ◽

Kinase Inhibitors ◽

Reporting System ◽

Adverse Event Reporting System ◽

Adverse Event Reporting ◽

Small Cell ◽

Small Cell Lung ◽

Event Reporting ◽

Anaplastic Lymphoma ◽

Spontaneous Reports

Download Full-text

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Targeted Oncology ◽

10.1007/s11523-021-00859-6 ◽

2022 ◽

Author(s):

Hai-Yan Tu ◽

Jifeng Feng ◽

Meiqi Shi ◽

Jun Zhao ◽

Yuyan Wang ◽

...

Keyword(s):

Final Analysis ◽

Open Label ◽

Phase Iiib ◽

Egfr Tki

Download Full-text

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study

Targeted Oncology ◽

10.1007/s11523-021-00860-z ◽

2021 ◽

Author(s):

David Waterhouse ◽

Laura Iadeluca ◽

Sneha Sura ◽

Keith Wilner ◽

Birol Emir ◽

...

Keyword(s):

Lung Cancer ◽

Observational Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Real World ◽

Small Cell ◽

Small Cell Lung ◽

Community Oncology

Download Full-text

Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Targeted Oncology ◽

10.1007/s11523-021-00864-9 ◽

2021 ◽

Author(s):

Matt Shirley

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

B Cell Malignancies ◽

Bruton Tyrosine Kinase

Download Full-text

MYL-1402O: A Bevacizumab Biosimilar

Targeted Oncology ◽

10.1007/s11523-021-00858-7 ◽

2021 ◽

Author(s):

Arnold Lee

Download Full-text

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Targeted Oncology ◽

10.1007/s11523-021-00857-8 ◽

2021 ◽

Author(s):

Matt Shirley

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

B Cell Malignancies ◽

Bruton Tyrosine Kinase

Download Full-text

Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma

Targeted Oncology ◽

10.1007/s11523-021-00861-y ◽

2021 ◽

Author(s):

Veronica Mollica ◽

Matteo Santoni ◽

Marc R. Matrana ◽

Umberto Basso ◽

Ugo De Giorgi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma

Download Full-text

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice

Targeted Oncology ◽

10.1007/s11523-021-00862-x ◽

2021 ◽

Author(s):

Lishi Lin ◽

Egbert F. Smit ◽

Adrianus J. de Langen ◽

Dorieke E. M. van Balen ◽

Jos H. Beijnen ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Practice ◽

Treatment Outcomes ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Trial ◽

Lung Cancer Patients ◽

Egfr Mutated

Download Full-text

Correction to: Durvalumab: A Review in Extensive-Stage SCLC

Targeted Oncology ◽

10.1007/s11523-021-00863-w ◽

2021 ◽

Author(s):

Zaina T. Al-Salama

Keyword(s):

Extensive Stage

Download Full-text

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Targeted Oncology ◽

10.1007/s11523-021-00855-w ◽

2021 ◽

Author(s):

Toshio Shimizu ◽

Yasutoshi Kuboki ◽

Chia-Chi Lin ◽

Kan Yonemori ◽

Tomoko Yanai ◽

...

Keyword(s):

Phase 1 ◽

East Asian ◽

Phase 1 Study ◽

Asian Patients ◽

East Asian Patients

Download Full-text

Targeted OncologyLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Springer-Verlag

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study

Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

MYL-1402O: A Bevacizumab Biosimilar

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice

Correction to: Durvalumab: A Review in Extensive-Stage SCLC

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Targeted Oncology
Latest Publications